Serious adverse events in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD)
Authors:
- E. DigiustoEDE. Digiusto
- A. ShakeshaftASA. Shakeshaft
- the NEPOD Research GroupTGthe NEPOD Research Group
- 13 February 2004
- Vol. 99 (4) , 450-460
Abstract
Aims The study estimated serious adverse event (SAE) rates among entrants to pharmacotherapies for opioid dependence, during treatment and after leaving treatment.Design A longitudinal study based on data from 12 trials included in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD).Participants and settings A total of 1244 heroin users and methadone patients treated in hospital, community and GP settings.Intervention Six trials included detoxification; all included treatment with methadone, buprenorphine, levo‐alpha‐acetyl‐methadol (LAAM) or naltrexone.Findings During 394 person‐years of observation, 79 SAEs of 28 types were recorded. Naltrexone participants experienced 39 overdoses per 100 person‐years after leaving treatment (44% occurred within 2 weeks after stopping naltrexone). This was eight times the rate recorded among participants who left agonist treatment. Rates of all other SAEs were similar during treatment versus out of treatment, for both naltrexone‐treated and agonist‐treated participants. Five deaths occurred, all among participants who had left treatment, at a rate of six per 100 person‐years. Total SAE rates during naltrexone and agonist treatments were similar (20, 14 per 100 person‐years, respectively). Total SAE and death rates observed among participants who had left treatment were three and 19 times the corresponding rates during treatment.Conclusions Individuals who leave pharmacotherapies for opioid dependence experience higher overdose and death rates compared with those in treatment. This may be due partly to a participant self‐selection effect rather than entirely to pharmacotherapy being protective. Clinicians should alert naltrexone treatment patients in particular about heroin overdose risks. Duty of care may extend beyond cessation of dosing.Keywords
This publication has 44 references indexed in Scilit:
- Morbidity associated with non‐fatal heroin overdoseAddiction, 2002
- Retention rate and illicit opioid use during methadone maintenance interventions: a meta-analysisDrug and Alcohol Dependence, 2002
- Accelerated withdrawal from methadone maintenance therapy using naltrexone and minimal sedation: a case-series analysisDrug and Alcohol Review, 2001
- National evaluation of pharmacotherapies for opioid dependence—why have we done it?Drug and Alcohol Review, 2001
- Heroin-related deaths in New South Wales, Australia, 1992–1996Drug and Alcohol Dependence, 2000
- An open trial of naltrexone for opiate dependenceDrug and Alcohol Review, 1998
- Deaths in the first two weeks of maintenance treatment in NSW in 1994: identifying cases of iatrogenic methadone toxicityDrug and Alcohol Review, 1998
- Determination of naltrexone dosage for narcotic agonist blockade in detoxified Asian addictsDrug and Alcohol Dependence, 1994
- Clinical experiences with 959 opiod-dependent patients treated with levo-alpha-acetymethadol (LAAM)Journal of Substance Abuse Treatment, 1986
- Methadyl acetate and methadone. An open comparisonJAMA, 1977